Omega Healthcare Investors, Inc.

DB:WX4 Stock Report

Market Cap: €10.2b

Omega Healthcare Investors Valuation

Is WX4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WX4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€70.99
Fair Value
47.9% undervalued intrinsic discount
15
Number of Analysts

Below Fair Value: WX4 (€36.99) is trading below our estimate of fair value (€70.99)

Significantly Below Fair Value: WX4 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WX4?

Key metric: As WX4 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for WX4. This is calculated by dividing WX4's market cap by their current earnings.
What is WX4's PE Ratio?
PE Ratio29x
EarningsUS$347.99m
Market CapUS$10.50b

Price to Earnings Ratio vs Peers

How does WX4's PE Ratio compare to its peers?

The above table shows the PE ratio for WX4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.5x
DOC Healthpeak Properties
47.1x-16.2%US$14.8b
ARE Alexandria Real Estate Equities
63x18.5%US$17.5b
CTRE CareTrust REIT
50.7x44.7%US$5.1b
SBRA Sabra Health Care REIT
41.2x15.8%US$4.1b
WX4 Omega Healthcare Investors
29x9.3%€10.5b

Price-To-Earnings vs Peers: WX4 is good value based on its Price-To-Earnings Ratio (29x) compared to the peer average (53.2x).

Price to Earnings Ratio vs Industry

How does WX4's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
WX4 29.0xIndustry Avg. 25.4xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: WX4 is expensive based on its Price-To-Earnings Ratio (29x) compared to the Global Health Care REITs industry average (25.3x).

Price to Earnings Ratio vs Fair Ratio

What is WX4's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WX4 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29x
Fair PE Ratio60.8x

Price-To-Earnings vs Fair Ratio: WX4 is good value based on its Price-To-Earnings Ratio (29x) compared to the estimated Fair Price-To-Earnings Ratio (60.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst WX4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€36.99
€41.19
+11.4%
8.0%€47.68€36.00n/a15
Jan ’26€35.80
€40.83
+14.0%
7.6%€46.96€35.46n/a15
Dec ’25€38.57
€40.46
+4.9%
8.2%€46.69€33.35n/a15
Nov ’25€38.96
€37.76
-3.1%
9.9%€45.05€32.18n/a15
Oct ’25€36.37
€35.68
-1.9%
8.6%€41.56€30.72n/a14
Sep ’25€35.68
€35.01
-1.9%
7.2%€39.81€30.76n/a13
Aug ’25€33.85
€31.97
-5.6%
7.0%€36.14€27.80n/a14
Jul ’25€31.48
€31.13
-1.1%
7.4%€35.46€26.13n/a14
Jun ’25€29.50
€30.25
+2.6%
6.3%€33.15€25.78n/a14
May ’25€28.45
€30.58
+7.5%
7.4%€34.51€26.12n/a14
Apr ’25€28.75
€30.52
+6.2%
7.4%€34.45€26.07n/a14
Mar ’25€28.30
€29.98
+5.9%
8.0%€34.10€25.80n/a15
Feb ’25€27.00
€29.94
+10.9%
7.2%€33.20€25.82n/a15
Jan ’25€27.70
€29.36
+6.0%
6.9%€32.59€25.35€35.8014
Dec ’24€29.35
€30.42
+3.6%
6.2%€33.77€27.38€38.5715
Nov ’24€31.20
€32.38
+3.8%
6.2%€35.98€28.40€38.9615
Oct ’24€31.40
€31.65
+0.8%
5.8%€34.27€28.56€36.3714
Sep ’24€30.20
€29.25
-3.1%
6.7%€32.71€25.44€35.6813
Aug ’24€28.85
€29.00
+0.5%
5.8%€31.91€25.53€33.8513
Jul ’24€28.00
€28.49
+1.7%
6.2%€30.23€23.82€31.4811
Jun ’24€27.45
€28.22
+2.8%
8.3%€30.76€23.30€29.5011
May ’24€24.05
€26.81
+11.5%
11.1%€32.67€21.78€28.4511
Apr ’24€24.96
€27.00
+8.2%
11.5%€33.21€22.14€28.7511
Mar ’24€25.05
€27.59
+10.2%
11.0%€33.96€22.64€28.3012
Feb ’24€26.69
€27.42
+2.7%
10.6%€33.16€23.03€27.0013
Jan ’24€26.00
€30.32
+16.6%
6.5%€33.87€26.34€27.7013
Analyst Price Target
Consensus Narrative from 15 Analysts
€41.91
Fair Value
11.7% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 08:21
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Omega Healthcare Investors, Inc. is covered by 35 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Amanda SweitzerBaird
David RodgersBaird
Steven ValiquetteBarclays